VYNE Therapeutics (VYNE) Competitors

$0.68 +0.00 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$0.68 0.00 (-0.16%)

As of 04:57 PM Eastern

VYNE vs. QTTB, BTMD, ETHZ, JATT, and EXOZ

Should you buy VYNE Therapeutics stock or one of its competitors? MarketBeat compares VYNE Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VYNE Therapeutics include Q32 Bio (QTTB), biote (BTMD), Flag Ship Acquisition (ETHZ), JATT Acquisition (JATT), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry.

How does VYNE Therapeutics compare to Q32 Bio?

VYNE Therapeutics (NASDAQ:VYNE) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Q32 Bio has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. Q32 Bio's return on equity of 149.23% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Q32 Bio	N/A	149.23%	34.50%

Q32 Bio has a consensus target price of $13.00, indicating a potential upside of 114.17%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts plainly believe Q32 Bio is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Q32 Bio	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 40.0% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Q32 Bio has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	39.85	-$26.48M	-$0.50	N/A
Q32 Bio	$53.74M	1.92	$29.82M	$2.66	2.28

In the previous week, VYNE Therapeutics had 1 more articles in the media than Q32 Bio. MarketBeat recorded 2 mentions for VYNE Therapeutics and 1 mentions for Q32 Bio. VYNE Therapeutics' average media sentiment score of 1.50 beat Q32 Bio's score of 0.55 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Q32 Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Q32 Bio has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

Summary

Q32 Bio beats VYNE Therapeutics on 12 of the 17 factors compared between the two stocks.

How does VYNE Therapeutics compare to biote?

biote (NASDAQ:BTMD) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

biote has a net margin of 8.29% compared to VYNE Therapeutics' net margin of -4,726.21%. biote's return on equity of -25.72% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

biote currently has a consensus target price of $2.75, suggesting a potential upside of 39.24%. Given biote's stronger consensus rating and higher probable upside, equities research analysts plainly believe biote is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

biote has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.41	$27.05M	$0.44	4.49
VYNE Therapeutics	$570K	39.85	-$26.48M	-$0.50	N/A

biote has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

In the previous week, VYNE Therapeutics had 1 more articles in the media than biote. MarketBeat recorded 2 mentions for VYNE Therapeutics and 1 mentions for biote. VYNE Therapeutics' average media sentiment score of 1.50 beat biote's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
biote	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

21.7% of biote shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 32.4% of biote shares are held by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

biote beats VYNE Therapeutics on 11 of the 16 factors compared between the two stocks.

How does VYNE Therapeutics compare to Flag Ship Acquisition?

Flag Ship Acquisition (NASDAQ:ETHZ) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, VYNE Therapeutics had 1 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 2 mentions for VYNE Therapeutics and 1 mentions for Flag Ship Acquisition. VYNE Therapeutics' average media sentiment score of 1.50 beat Flag Ship Acquisition's score of 0.88 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Flag Ship Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Flag Ship Acquisition has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

Flag Ship Acquisition has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flag Ship Acquisition	$4.11M	17.25	-$6.17M	-$159.65	N/A
VYNE Therapeutics	$570K	39.85	-$26.48M	-$0.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Flag Ship Acquisition has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Flag Ship Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flag Ship Acquisition	N/A	-185.71%	-83.12%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

4.1% of Flag Ship Acquisition shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 15.1% of Flag Ship Acquisition shares are owned by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

VYNE Therapeutics beats Flag Ship Acquisition on 9 of the 14 factors compared between the two stocks.

How does VYNE Therapeutics compare to JATT Acquisition?

VYNE Therapeutics (NASDAQ:VYNE) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

JATT Acquisition has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. JATT Acquisition's return on equity of -49.58% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
JATT Acquisition	N/A	-49.58%	2.84%

JATT Acquisition has lower revenue, but higher earnings than VYNE Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	39.85	-$26.48M	-$0.50	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

In the previous week, VYNE Therapeutics had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 2 mentions for VYNE Therapeutics and 1 mentions for JATT Acquisition. VYNE Therapeutics' average media sentiment score of 1.50 beat JATT Acquisition's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

VYNE Therapeutics and JATT Acquisition tied by winning 5 of the 10 factors compared between the two stocks.

How does VYNE Therapeutics compare to eXoZymes?

VYNE Therapeutics (NASDAQ:VYNE) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

In the previous week, VYNE Therapeutics and VYNE Therapeutics both had 2 articles in the media. VYNE Therapeutics' average media sentiment score of 1.50 beat eXoZymes' score of 0.69 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

eXoZymes has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
eXoZymes	N/A	-220.63%	-141.26%

eXoZymes has lower revenue, but higher earnings than VYNE Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	39.85	-$26.48M	-$0.50	N/A
eXoZymes	$70K	1,150.86	-$9.16M	-$1.14	N/A

83.8% of VYNE Therapeutics shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 72.4% of eXoZymes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

VYNE Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.85, indicating that its share price is 185% more volatile than the broader market.

Summary

VYNE Therapeutics beats eXoZymes on 8 of the 13 factors compared between the two stocks.

Get VYNE Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VYNE vs. The Competition

Export

Metric	VYNE Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.56M	$2.99B	$6.25B	$12.23B
Dividend Yield	N/A	1.96%	2.80%	5.27%
P/E Ratio	-1.36	17.04	20.79	25.04
Price / Sales	39.85	251.21	531.21	72.18
Price / Cash	N/A	57.15	43.09	54.25
Price / Book	0.92	4.39	9.81	6.83
Net Income	-$26.48M	$74.99M	$3.55B	$335.69M
7 Day Performance	3.21%	-4.89%	-2.07%	-2.03%
1 Month Performance	11.64%	-8.30%	-3.90%	-1.90%
1 Year Performance	-44.17%	28.66%	29.39%	27.36%

VYNE Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VYNE VYNE Therapeutics	1.1672 of 5 stars	$0.68 +0.7%	N/A	-44.6%	$22.56M	$570K	N/A	30	Positive News Earnings Report
QTTB Q32 Bio	4.0238 of 5 stars	$5.81 +12.2%	$13.00 +123.8%	+224.9%	$87.83M	$53.74M	2.18	39	Analyst Forecast High Trading Volume
BTMD biote	3.8592 of 5 stars	$2.20 -0.5%	$2.75 +25.0%	-53.4%	$87.41M	$192.22M	5.00	194
ETHZ Flag Ship Acquisition	0.1849 of 5 stars	$4.49 -2.6%	N/A	N/A	$85.36M	$4.11M	N/A	7	Gap Up
JATT JATT Acquisition	N/A	$10.75 +2.2%	N/A	+868.5%	$83.85M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VYNE) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VYNE Therapeutics (VYNE) Competitors

VYNE vs. QTTB, BTMD, ETHZ, JATT, and EXOZ

How does VYNE Therapeutics compare to Q32 Bio?

Summary

How does VYNE Therapeutics compare to biote?

Summary

How does VYNE Therapeutics compare to Flag Ship Acquisition?

Summary

How does VYNE Therapeutics compare to JATT Acquisition?

Summary

How does VYNE Therapeutics compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYNE vs. The Competition

VYNE Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VYNE Therapeutics (VYNE) Competitors

VYNE vs. QTTB, BTMD, ETHZ, JATT, and EXOZ

How does VYNE Therapeutics compare to Q32 Bio?

Is VYNE or QTTB more profitable?

Do analysts prefer VYNE or QTTB?

Do institutionals and insiders believe in VYNE or QTTB?

Which has better valuation & earnings, VYNE or QTTB?

Does the media favor VYNE or QTTB?

Which has more risk and volatility, VYNE or QTTB?

Summary

How does VYNE Therapeutics compare to biote?

Is BTMD or VYNE more profitable?

Do analysts prefer BTMD or VYNE?

Which has stronger valuation & earnings, BTMD or VYNE?

Which has more risk & volatility, BTMD or VYNE?

Does the media prefer BTMD or VYNE?

Do institutionals & insiders believe in BTMD or VYNE?

Summary

How does VYNE Therapeutics compare to Flag Ship Acquisition?

Does the media prefer ETHZ or VYNE?

Which has more risk & volatility, ETHZ or VYNE?

Which has better valuation and earnings, ETHZ or VYNE?

Do analysts recommend ETHZ or VYNE?

Is ETHZ or VYNE more profitable?

Do insiders and institutionals have more ownership in ETHZ or VYNE?

Summary

How does VYNE Therapeutics compare to JATT Acquisition?

Do analysts rate VYNE or JATT?

Do insiders & institutionals believe in VYNE or JATT?

Is VYNE or JATT more profitable?

Which has stronger valuation & earnings, VYNE or JATT?

Does the media prefer VYNE or JATT?

Summary

How does VYNE Therapeutics compare to eXoZymes?

Does the media refer more to VYNE or EXOZ?

Is VYNE or EXOZ more profitable?

Which has higher earnings & valuation, VYNE or EXOZ?

Do institutionals and insiders believe in VYNE or EXOZ?

Do analysts recommend VYNE or EXOZ?

Which has more volatility and risk, VYNE or EXOZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYNE vs. The Competition

VYNE Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools